Else Nutrition - interview with the CEO discussing the recent financing (link below). Among other things, it looks like the clinical trials required by the FDA have become more expensive than expected. She said these clinical trials should start in the next several months.
Having the future of the company so dependent upon clinical trials and the FDA tends to give BABYF the risk profile of a biotech stock, at least for now -
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.